Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumab-based treatment in patients with HER-2/neu-positive metastatic breast cancer

被引：0
|
作者：
Musolino, A. [1 ]
Naldi, N. [1 ]
Bortesi, B. [1 ]
Capelletti, M. [1 ]
Pezzuolo, D. [1 ]
Michiara, M. [1 ]
Missale, G. [1 ]
Laccabue, D. [1 ]
Zerbini, A. [1 ]
Camisa, R. [1 ]
Ardizzoni, A. [1 ]
机构：
[1] Univ Hosp Parma, Parma, Italy
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2007年 / 103卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：119 / 120
页数：2
相关论文
共 50 条
  • [21] A Review of Trastuzumab-Based Therapy in Patients with HER2-positive Metastatic Breast Cancer
    Church, David N.
    Price, Chris G. A.
    CLINICAL MEDICINE INSIGHTS-THERAPEUTICS, 2009, 1 : 557 - 570
  • [22] Decline in serum HER-2/neu predicts response to trastuzumab-based therapy
    Ali, S. M.
    Brault, D.
    Brown-Shimer, S.
    Carney, W.
    Esteva, F. J.
    Fornier, M.
    Gligorov, J.
    Hamer, P.
    Harris, L.
    Kostler, W. J.
    Leitzel, K.
    Lotz, J. P.
    Luftner, D.
    Pichon, M. F.
    Thiel, R. P.
    Tse, C.
    Wheler, J.
    Lipton, A.
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2007, 22 (01): : 75 - 76
  • [23] Decline in serum HER-2/neu predicts response to trastuzumab-based therapy
    Leitzel, K.
    Esteva, F.
    Fornier, M.
    Gligorov, J.
    Harris, L.
    Kostler, W.
    Luftner, D.
    Pichon, M.
    Tse, C.
    Lipton, A.
    EJC SUPPLEMENTS, 2006, 4 (12): : 102 - 102
  • [24] Trastuzumab-based treatment of HER2-positive metastatic gastric cancer
    Dogan, I.
    Karabulut, S.
    Tastekin, D.
    Paksoy, N.
    Sakar, B.
    Vatansever, S.
    ANNALS OF ONCOLOGY, 2020, 31 : S205 - S205
  • [25] Hidden HER-2/neu-positive breast cancer: How to maximize detection
    Carney, Walter P.
    IDRUGS, 2009, 12 (04) : 238 - 242
  • [26] HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?
    Widakowich, Christian
    Dinh, Phuong
    de Azambuja, Evandro
    Awada, Ahmad
    Piccart-Gebhart, Martine
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2008, 8 (05) : 488 - 496
  • [27] Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in patients with HER2-positive operable breast cancer
    Musolino, Antonino
    Guarneri, Valentina
    Naldi, Nadia
    Bortesi, Beatrice
    Boggiani, Daniela
    Sgargi, Paolo
    Generali, Daniele G.
    Piacentini, Federico
    Dieci, Maria V.
    Ambroggi, Massimo
    Cagossi, Katia
    Gianni, Lorenzo
    Sarti, Samanta
    Bisagni, Giancarlo
    Frassoldati, Antonio
    Conte, Pierfranco
    Ardizzoni, Andrea
    CANCER RESEARCH, 2015, 75
  • [28] HER-2-positive metastatic breast cancer: Optimizing trastuzumab-based therapy
    Jackisch, Christian
    ONCOLOGIST, 2006, 11 : 34 - 41
  • [29] The effect of HER-2/neu inhibition on prolonging clinical benefit with fulvestrant treatment for metastatic estrogen receptor positive breast cancer patients treated with trastuzumab
    Charif, Mahmoud
    Lower, Elyse E.
    Kennedy, Diane
    Kumar, Harriet
    Khan, Shugufta
    Radhakrishnan, Neetu
    Zhang, Xiaoting
    CANCER RESEARCH, 2015, 75
  • [30] Serum HER-2/NEU decline predicts improved response to trastuzumab-based therapy (serum HER-2/NEU study group)
    Ali, S. M.
    Esteva, F. J.
    Fornier, M.
    Harris, L.
    Kostler, W. J.
    Lotz, J. P.
    Luftner, D.
    Pichon, M. F.
    Tse, C.
    Lipton, A.
    ANNALS OF ONCOLOGY, 2006, 17 : 69 - 69
12345